82 results
Page 4 of 5
424B3
9l99yu kipifa
15 Oct 18
Prospectus supplement
12:00am
424B5
y8677
13 Sep 18
Prospectus supplement for primary offering
12:00am
6-K
EX-99.2
05mljp ztaf
2 Aug 18
Current report (foreign)
4:03pm
6-K
EX-99.1
x17zrn q6no
2 May 18
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
6:00am
6-K
EX-99.2
x7mlsp oyyv2usw
27 Apr 18
Galapagos reports first quarter 2018 results
12:00am
6-K
EX-3.1
njn5fvjp
18 Apr 17
Galapagos announces launch of proposed public offering
12:00am
424B5
a887 ajo0c
18 Apr 17
Prospectus supplement for primary offering
12:00am
424B5
15pbb51q
17 Apr 17
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
qh59n
14 Jul 16
FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016
12:00am
20-F
EX-1.1
zwmkzl8z3yu4ojmf
25 Mar 16
Annual report (foreign)
12:00am
20-F
470qyr1h
25 Mar 16
Annual report (foreign)
12:00am
DRS/A
EX-10
nv3d5q
4 Mar 15
Draft registration statement (amended)
12:00am
DRS/A
EX-10
afeqh4jus9bni9eq
4 Mar 15
Draft registration statement (amended)
12:00am
DRS
EX-10
ukjn4
6 Feb 15
Draft registration statement
12:00am
DRS
EX-3
sqyn17z563zb5 z5xmc5
6 Feb 15
Draft registration statement
12:00am
DRS
EX-10
qm937gieb6
6 Feb 15
Draft registration statement
12:00am
DRS
atwesso3nq1mnoa
6 Feb 15
Draft registration statement
12:00am